Literature DB >> 31102548

Seizure and status epilepticus in chronic subdural hematoma.

Sae-Yeon Won1, Daniel Dubinski1, Lisa Sautter1, Elke Hattingen2, Volker Seifert1, Felix Rosenow3, Thomas Freiman1, Adam Strzelczyk3, Juergen Konczalla1.   

Abstract

BACKGROUND: Acute symptomatic seizure (ASz) and status epilepticus (SE) are serious conditions associated with poor quality of life, with unfavorable psychosocial and functional outcome. Chronic subdural hematoma (cSDH) is a common neurosurgical disease related to those complications; therefore, we aimed to evaluate incidence, predictors of ASz/SE, and outcome in this cohort.
METHODS: We retrospectively analyzed patient diagnosed cSDH between 2010 and 2017. Beside their incidence of ASz/SE, patient characteristics, symptoms at admission, comorbidities, and all previously published relevant parameters were assessed. Recurrence rate and functional outcome were analyzed at hospital discharge and 90-day follow-up.
RESULTS: A total of 375 patients were included; incidence of ASz was 15.2% and of SE, 1.9%. In the univariate analysis, drainage insertion (P =  0.004; OR = 0.3) was a significant negative predictor for ASz/SE and multivariate analysis, including all significant parameters, designated GCS ≤13 at admission (P = 0.09; OR = 1.9), remote stroke (P = 0.009; OR = 2.9), and recurrence rate within 14 days (P = 0.001; OR = 3.3; with an incidence of 13%) as independent predictors for ASz/SE. Overall, patients with ASz/SE had significantly unfavorable outcome at discharge (54.7%; P < 0.001) and follow-up (39.5%; P < 0.001) with only slight improvement. Late seizures occurred in 3.8% within follow-up period. Any patient with SE had an unfavorable outcome at discharge without any improvement at follow-up having a mortality rate of 14.2%.
CONCLUSION: Independent predictors for ASz/SE are GCS ≤13 at admission, remote stroke, and recurrent hematoma in patients with cSDH, which is associated with worse functional outcome, particularly those with SE. Due to the higher rate of seizures than recurrence rate, a routine pre- and postoperative EEG besides CT is recommended.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  EEG; chronic subdural hematoma; functional outcome; predictors; seizures; status epilepticus

Mesh:

Year:  2019        PMID: 31102548     DOI: 10.1111/ane.13131

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Transient neurological deficit in patients with chronic subdural hematoma: a retrospective cohort analysis.

Authors:  Jurre Blaauw; Heleen M den Hertog; Josje M van Zundert; Niels A van der Gaag; Korné Jellema; Ruben Dammers; Kuan H Kho; Rob J M Groen; Hester F Lingsma; Joukje van der Naalt; Bram Jacobs
Journal:  J Neurol       Date:  2022-01-09       Impact factor: 6.682

Review 2.  Role of prophylactic antiepileptic drugs in chronic subdural hematoma-a systematic review and meta-analysis.

Authors:  Deivanai Sundaram Nachiappan; Kanwaljeet Garg
Journal:  Neurosurg Rev       Date:  2020-09-10       Impact factor: 3.042

3.  External validation and modification of the Oslo grading system for prediction of postoperative recurrence of chronic subdural hematoma.

Authors:  Sae-Yeon Won; Daniel Dubinski; Michael Eibach; Florian Gessler; Eva Herrmann; Fee Keil; Volker Seifert; Juergen Konczalla; Bedjan Behmanesh
Journal:  Neurosurg Rev       Date:  2020-02-28       Impact factor: 3.042

4.  Factors correlated with the postoperative recurrence of chronic subdural hematoma: An umbrella study of systematic reviews and meta-analyses.

Authors:  Fulei Zhu; Haifeng Wang; Wenchen Li; Shuai Han; Jiangyuan Yuan; Chunyun Zhang; Zean Li; Guangyan Fan; Xuanhui Liu; Meng Nie; Li Bie
Journal:  EClinicalMedicine       Date:  2021-12-20

Review 5.  Seizures and epilepsy in patients with ischaemic stroke.

Authors:  Johann Philipp Zöllner; Friedhelm C Schmitt; Felix Rosenow; Konstantin Kohlhase; Alexander Seiler; Adam Strzelczyk; Hermann Stefan
Journal:  Neurol Res Pract       Date:  2021-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.